Integra LifeSciences (NSDQ:IART) this week acquired Arkis BioSciences and its line of neurosurgery devices for an undisclosed amount.
Knoxville, Tenn.-based Arkis makes the CerebroFlo external ventricular drainage catheter that uses its Endexo anti-thrombus additive to prevent blood clots.
“Neurocritical care is an important area of focus for Integra. We recently introduced our CereLink intracranial pressure monitor and invested in clinical specialists to better support neurocritical care teams,” Codman Specialty Surgical president Dan Reuvers said in prepared remarks. “Today’s acquisition expands our leading portfolio to better treat patients and underscores our commitment to addressing unmet needs in patient care.”
“The introduction of the CerebroFlo EVD catheter first established the benefits of Endexo in neurocritical care,” added CEO Chad Seaver. “As a world leader in neurosurgery, Integra is the right choice to extend the reach of this important technology to patients and clinicians worldwide.”
Integra said it doesn’t expect the acquisition to affect its finances this year.